[The new immunosuppressive drugs for renal transplantation: inhibitors of the mammalian target of rapamycin (mTOR) and anti-thymocyte globulin (Thymoglobulin)].

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Nihon Jinzo Gakkai shi

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 23631297
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Biologics in organ transplantation

  2012cited by this paper
• Everolimus: preventing organ rejection in adult kidney transplant recipients

  2012cited by this paper
• Clinical Outcomes in Kidney Transplant Recipients Receiving Long‐Term Therapy With Inhibitors of the Mammalian Target of Rapamycin

  2012cited by this paper
• mTOR signaling in growth control and disease.

  2012cited by this paper
• Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials

  2011cited by this paper
• 25 Years and New Frontiers in Solid Organ Transplantation and Haematology

  2011cited by this paper
• Report of a Joint ESOT and AST Meeting: Highlights in Biologic Agents and Transplantation

  2011cited by this paper
• Immune Reconstitution Following Rabbit Antithymocyte Globulin

  2010cited by this paper
• The Jak Inhibitor CP‐690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells

  2010cited by this paper
• Antithymocyte globulin use for treatment of biopsy confirmed acute rejection is associated with prolonged renal allograft survival

  2010cited by this paper
• Immunosuppressive Drugs in Kidney Transplantation

  2009cited by this paper
• Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor.

  2009cited by this paper
• The effect of rabbit anti-thymocyte globulin induction therapy on regulatory T cells in kidney transplant patients.

  2009cited by this paper
• Calcineurin‐Inhibitor‐Free Immunosuppression Based on the JAK Inhibitor CP‐690,550: A Pilot Study in De Novo Kidney Allograft Recipients

  2009cited by this paper
• Presence of FoxP3+ regulatory T Cells predicts outcome of subclinical rejection of renal allografts.

  2008cited by this paper
• A Prospective, Randomized, Double-Blinded Comparison of Thymoglobulin Versus Atgam for Induction Immunosuppressive Therapy: 10-Year Results

  2008cited by this paper
• Endothelial Cells in Allograft Rejection

  2008cited by this paper
• Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients

  2008cited by this paper
• Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond

  2007cited by this paper
• Memory T cells in allograft rejection.

  2007cited by this paper
• A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells.

  2006cited by this paper
• Immunocompetent T‐Cells with a Memory‐Like Phenotype are the Dominant Cell Type Following Antibody‐Mediated T‐Cell Depletion

  2005cited by this paper
• Biological effects of induction immunosuppression.

  2004cited by this paper
• Induction of immunosuppression with polyclonal antithymocyte globulins: an overview.

  2003cited by this paper
• Induction therapy by anti‐thymocyte globulin (rabbit) in renal transplantation: a 1‐yr follow‐up of safety and efficacy

  2003cited by this paper
• MECHANISMS INVOLVED IN ANTITHYMOCYTE GLOBULIN IMMUNOSUPPRESSIVE ACTIVITY IN A NONHUMAN PRIMATE MODEL 1

  2001cited by this paper

• No citing papers are available for this paper.